Gettysburg Cancer Center

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Lung cancer6 trials
• Head and neck cancer3 trials
• Gastric and oesophageal cancer2 trials
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Mantle cell lymphoma1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Ovarian cancer1 trial
• Pancreatic cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 24 trials
• Phase 33 trials
• Phase 1/21 trial

Status

• Terminated4 trials
• Completed3 trials
• Active, not recruiting2 trials

Lead sponsor

• EMD Serono Research & Development Institute, Inc.2 trials
• Astellas Pharma Global Development, Inc.1 trial
• Biodesix, Inc.1 trial
• ImmunityBio, Inc.1 trial
• Incyte Corporation1 trial
• and 3 more

Running trials

• Active, not recruiting

  A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

  NCT04225117· Phase 2· Astellas Pharma Global Development, Inc.· Source

• Active, not recruiting

  Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects

  NCT03289780· Biodesix, Inc.· Source

Closed trials

• Terminated

  Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

  NCT05169437· Phase 2· Tempus AI· Source

• Terminated

  A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

  NCT04875806· Phase 1/2· NextCure, Inc.· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

  NCT03940703· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Stemline Therapeutics, Inc.· Source

• Terminated

  Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

  NCT03520686· Phase 3· ImmunityBio, Inc.· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

  NCT03235544· Phase 2· Incyte Corporation· Source